NBIX Neurocrine Biosciences, Inc.

-0.11  -0%
Previous Close 53.64
Open 53.71
Price To book 18.99
Market Cap 4.71B
Shares 88,074,000
Volume 750,930
Short Ratio 4.36
Av. Daily Volume 1,294,330

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17827314
  2. 8-K - Current report 17827226
  3. 8-K - Current report 17806088
  4. 8-K - Current report 17781111
  5. DEF 14A - Other definitive proxy statements 17774013

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 planned for 2017.
Essential Tremor
NDA filing planned - license agreement with BIAL announced February 9, 2017.
Parkinson's disease
Phase 2 data released May 23 - primary endpoint not met.
Tourette syndrome - juvenile
Phase 2 data released January 18, 2017 did not meet primary endpoint.
Tourette syndrome - adults
Phase 3 initiated by partner Abbvie in January 2016. Data due late 2017.
Uterine Fibroids
First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA Filing due 3Q 2017.
Approved April 11, 2017.
Tardive dyskinesia

Latest News

  1. Nuerocrine's Tourette's syndrome drug trial fails
  2. Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA® For Treatment of Tourette Syndrome
  3. What Drug Approval Means for Neurocrine Biosciences
  4. Neurocrine Announces INGREZZA® (valbenazine) Capsules Pharmacokinetic Profile and Long-Term Data to be Presented at the 2017 American Psychiatric Association Annual Meeting
  5. AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis
  6. Edited Transcript of NBIX earnings conference call or presentation 9-May-17 9:00pm GMT
  7. NBIX: INGREZZA™ Launch Commences…
  8. Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference
  9. Neurocrine reports 1Q loss
  10. Neurocrine Biosciences Reports First Quarter 2017 Results
  11. Investor Network: Neurocrine Biosciences, Inc. to Host Earnings Call
  12. Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2017 Results
  13. Why Neurocrine is charging twice as much for its new drug as it said it would
  14. Neurocrine Biosciences, Inc. Announces Closing of Offering of $517.5 Million of Convertible Senior Notes
  15. Neurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as expected
  16. The 3 Best Pharmaceutical Stocks to Buy in 2017
  17. Neurocrine Biosciences, Inc. Prices $450.0 Million Convertible Senior Notes Offering
  18. Neurocrine Announces Proposed Convertible Senior Notes Offering
  19. Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates
  20. Neurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting